Global Central Nervous System Treatment Market

Global Central Nervous System Treatment Market Size, Share, Growth Analysis, By Disease Type(Neurovascular Diseases, CNS Trauma), By Drug class(Immunomodulatory drugs, interferons), By Drug Type(Biologics, Non-Biologics) - Industry Forecast 2023-2030


Report ID: SQMIG35B2179 | Region: Global | Published Date: February, 2024
Pages: 260 | Tables: 96 | Figures: 76

Global Central Nervous System Treatment Market Insights

Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2021 and is poised to grow from USD 128.29 billion in 2022 to USD 209.2 billion by 2030, growing at a CAGR of 6.3% in the forecast period (2023-2030).

The pursuit of sedentary and busy lifestyle in the global population has led in the prevalence of chronic disorders and exposure to central nervous system disorders like schizophrenia and Alzheimer's. This indicates thaThe central nervous system treatment often involves a multidisciplinary approach which is inclusive of neurosurgeons, neurologists, and physical therapists. Collaboration among specialists ensures a comprehensive care and a holistic approach to the treatment. Ongoing research in the field of neuroscience and CNS disorders continue to contribute to the development of novel treatment options. This includes continuous advancements in medical surgical techniques, gene therapies, and neuroimaging techniques. t the healthcare sector is equipped to tackle lifestyle related diseases and prepares the market with options for patients with significant treatment opportunities. 

Global treatment rates for illnesses related to the central nervous system (CNS) is predicted to rise on the account of diagnostic and therapeutic advances. Additionally, over the upcoming years, market growth is likely to be boosted due to the growing prevalence of central nervous system illnesses and the rising demand for efficient therapy choices.

According to WHO research more than 1 billion individuals worldwide are affected by central nervous system disorders including Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and stroke. All of the major pharmaceutical companies have invested and developed innovative medicines for the treatment of CNS illnesses as a result of the significant unmet medical demand.

An increase in treatment rates, particularly in low- and middle-income countries, has been brought on by the increasing approval of generic medications as a result of the patent expirations of important products like Copaxone and Invega. For instance, the FDA approved two new generic versions of Copaxone in 2018, which is projected to significantly intensify market competition for CNS treatments. The introduction of novel drugs into the market for treating the central nervous system is encouraged by regulatory standards and rigorous clinical trials. The effectiveness, dose, formulation, and side effects of these medications are all closely watched. For the treatment of individuals with malignant gliomas, the U.S. FDA has designated CNS Pharmaceuticals' berubicin as an orphan medication.

In the past ten years, there have been significant R&D activities in the CNS treatment sector, which have led to the launch of innovative drug delivery systems. The adoption of a novel therapy to treat illnesses of the central nervous system is anticipated to expand as a result of developments in drug delivery methods.

US Central Nervous System Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

Market snapshot - 2023-2030

Global Market Size

USD 120.64 billion

Fastest Growth

immunomodulatory drugs

Growth Rate

6.3% CAGR

Global Central Nervous System Treatment Market ($ Bn)
Country Share for North America (%)
Global Central Nervous System Treatment Market BY Drug class (%)

To get more reports on the above market click here to Buy The Report

Global Central Nervous System Treatment Market Segmental Analysis

The global central nervous system treatment market segmentation is based on disease type, drug class, drug type and region. Based on disease type the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, CNS Cancer and other segments. Based on drug class, the market is segregated into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, analgesics and other segments. Based on drug type the market segmentation spans biologics and non-biologics. Based on region the global central nervous system treatment market segmentation spans North America, Europe, Asia-Pacific and Rest of the world.

Central Nervous System Treatment Market Analysis by Disease type

Due to the increasing prevalence of neurological disorders, including multiple sclerosis and Alzheimer's disease the neurodegenerative diseases dominated the market. Growing R&D expenditures with the goal of creating prospective therapeutic candidates for the treatment of multiple sclerosis, Alzheimer's, etc. are also a component in the market's quick growth.

As an illustration, Dyno Therapeutics and Roche announced a collaborative license agreement to use Dyno's CapsidMap platform to develop next-generation adeno-associated virus (AAV) vectors for gene therapies for CNS disorders and liver-directed therapies for both Roche and Spark Therapeutics, (a member of the Roche Group) product portfolio.

Central Nervous System Treatment Market Analysis by Drug Type

Non-biologics dominated the global market and the dominance is caused by the regulatory body imposing less regulations than it did for the approval of biologics. Additionally, Biogen's Tecfidera, which treats multiple sclerosis, has the largest revenues due to its widespread prescription in the non-biologics market worldwide. During the projection period, the rising prevalence of neurological illnesses, strong government support and favorable health reimbursement are additional major growth drivers for the non-biologics market. Additionally, elements including the availability of prospective pipeline candidates and the government assistance in creation and approval of biologic CNS medications are anticipated to promote the expansion of the biologics segment.

Global Central Nervous System Treatment Market BY Drug class, 2021 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Global Central Nervous System Treatment Market Regional Insights

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.

With the second leading position, Europe followed the United States. This can be attributed to the advantageous reimbursement practices and broad access to healthcare provided by the public healthcare systems like the National Health Service (NHS) of the United Kingdom. A spectacular CAGR is predicted for the Asia-Pacific countries due to a number of causes, including an ageing population, changing healthcare infrastructure, a higher engagement of countries that produce biosimilar and over-the-counter drugs, and an increase in neurological illnesses.

Global Central Nervous System Treatment Market By Region, 2023-2030
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Central Nervous System Treatment Market Dynamics

Central Nervous System Treatment Market Drivers

Increasing prevalence of mental diseases and pipeline researches is substantially driving the market growth.

  • The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050. 
  • Over the course of the forecast period, market growth is predicted to be fueled by potential product launches for the treatment of neurological illnesses. It is anticipated that these planned launches would improve access to healthcare in developing nations. For instance, Lenabasum is presently undergoing a Phase 3 clinical research by Corbus Pharmaceuticals Inc. to assess its safety and effectiveness in the management of diffuse cutaneous systemic sclerosis. 

Central Nervous System Treatment Market Restraints

High cost of drug development and the regulatory hurdles to restrain the growth

  • Investments in the therapeutic research and development are higher than other therapeutic illness areas. Since the therapies created for treating the central nervous system requires high accuracy, there is a limited availability of medical professionals. To develop a CNS related drug that affects brain and behaviour, the drug approval has a lengthy approval process which can take years to finalize.
  • The field of neuroscience is backed by research and intense work related to understanding a particular subject in the field. However, poor or limited understanding can create diversions and limit the ability of the company to receive timely approvals and can cause delay in rolling out a vaccine to treat CNS disorders.

Request Free Customization of this report to help us to meet your business objectives.

Global Central Nervous System Treatment Market Competitive Landscape

Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses.

Central Nervous System Treatment Market Top Players Company Profiles

  • Pfizer Inc.
  • Novartis International AG
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Sanofi S.A.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Biogen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Ipsen S.A.
  • Lundbeck A/S
  • Otsuka Holdings Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Central Nervous System Treatment Market Recent Developments

  • In June 2021, agreement was made between GSK and iTeos Therapeutics to create and market EOS-448, an anti-TIGIT monoclonal antibody that will allow for cutting-edge immuno-oncology combinations.
  • In April 2021, The National Medical Products Administration (NMPA) granted Biogen permission to expand its presence in China by approving the use of the drug TECFIDERA (dimethyl fumarate) to treat relapsed multiple sclerosis.
  • In March 2021, Johnson & Johnson received permission from the U.S. FDA to introduce Ponvory as a daily oral medication for the treatment of multiple sclerosis.

Global Central Nervous System Treatment Key Market Trends

  • Improvements in Diagnosis and Therapeutics: The development of the therapeutics market for the central nervous system is being fuelled by improvements in diagnostics, therapies, and drug discovery approaches. 
  • Investments of Pharmaceutical Companies: The need for effective CNS therapeutic options is growing, which encourages major pharmaceutical companies to invest in R&D and pave the path for future expansion. 
  • High Prevalence of Mental Illness: The prevalence of mental illness, the rise in lifestyle-related CNS disorders, and the rise in the senior population are further factors driving the expansion of the global market. The rate of acute psychological discomfort in adolescents and young adults has increased over the past few years, which has increased the demand for CNS therapies globally.

Global Central Nervous System Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to the global central nervous system market report analysis, the global market is poised to witness significant growth opportunities due to availability of treatment options, and a large patient pool. In addition, the market expansion strategies pursued by the key players represent growth factors and are likely to attract global attention.

Report Metric Details
Market size value in 2021 USD 120.64 billion
Market size value in 2030 USD 209.2 billion
Growth Rate 6.3%
Base year 2021
Forecast period 2023-2030
Forecast Unit (Value) USD Billion
Segments covered
  • Disease Type
    • Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative diseases, CNS Cancer, Others
  • Drug class
    • Immunomodulatory drugs, interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Analgesics, Others
  • Drug Type
    • Biologics, Non-Biologics
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Pfizer Inc.
  • Novartis International AG
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Sanofi S.A.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Biogen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Ipsen S.A.
  • Lundbeck A/S
  • Otsuka Holdings Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Central Nervous System Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Central Nervous System Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Central Nervous System Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Central Nervous System Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Central Nervous System Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Central Nervous System Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2021 and is poised to grow from USD 128.29 billion in 2022 to USD 209.2 billion by 2030, growing at a CAGR of 6.3% in the forecast period (2023-2030).

Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses. 'Pfizer Inc.', 'Novartis International AG', 'Johnson & Johnson', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'AbbVie Inc.', 'Sanofi S.A.', 'Eli Lilly and Company', 'AstraZeneca plc', 'Biogen Inc.', 'Teva Pharmaceutical Industries Ltd.', 'UCB S.A.', 'Boehringer Ingelheim International GmbH', 'Bristol-Myers Squibb Company', 'Ipsen S.A.', 'Lundbeck A/S', 'Otsuka Holdings Co., Ltd.', 'Sunovion Pharmaceuticals Inc.', 'Takeda Pharmaceutical Company Limited', 'Vertex Pharmaceuticals Incorporated'

The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050. 

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Central Nervous System Treatment Market

Product ID: SQMIG35B2179

$5,300
BUY NOW GET FREE SAMPLE